A biotechnology company in Scotland, backed by Archangel Investors Ltd, made its first public appearance on 8 June as a potential player in the rapidly expanding field of antibody-drug conjugates (ADCs). Emerging from stealth mode, Bead BioPharma Ltd disclosed its leadership and technology for the first time. The company’s interim chief executive is Dan Ozanne a serial entrepreneur, and its chair is Mike Sun. Mr Sun formerly worked for Seattle Genetics Inc (now Seagen), a pioneer in ADC field. Bead BioPharma has reportedly raised $1.14 million since its founding in 2023.
